Treatment and prophylaxis of allergic seasonal conjunctivitis in adults and children over 4 years of age. Treatment of symptoms of perennial allergic conjunctivitis in adults and children over 12 years of age.
Composition:
1 ml drops contain 0.5 mg azelastine hydrochloride. The preparation contains benzalkonium chloride.
Action:
Antiallergic drug for topical use. Azelastine, a derivative of phthalazinone, is a compound with a strong and long-lasting antiallergic effect. It acts antagonistically, selectively on H-receptors1. After topical administration to the eyes, the drug also has anti-inflammatory effects. Azelastine reduces the synthesis or release of chemical mediators involved in the early and late stages of the allergic reaction, e.g. leukotrienes, histamine, PAF and serotonin.
Contraindications:
Hypersensitivity to azelastine hydrochloride or to any of the excipients.
Precautions:
The drug is not indicated for the treatment of eye infections. The preparation contains benzalkonium chloride, which may, however, cause punctate keratitis and / or toxic ulcerative keratitis. In addition, benzalkonium chloride may cause eye irritation and discoloration of soft contact lenses. Do not wear contact lenses while using the medicine.
Pregnancy and lactation:
Caution should be exercised when using the drug during pregnancy. Small amounts of azelastine are excreted in human breast milk, which is why it is not recommended for women who are breastfeeding.
Side effects:
Common: eye irritation. Uncommon: bitter taste in the mouth. Very rare: allergic reactions.
Dosage:
Seasonal allergic conjunctivitis: adults and children over 4 years: usually 1 drop in each eye 2 times a day; if necessary, this dose can be increased to 1 drop 4 times a day. The drug can be administered prophylactically before anticipated exposure to an allergen.All year long allergic conjunctivitis: adults and children over 12: usually 1 drop in each eye 2 times a day. If necessary, this dose can be increased to 1 drop 4 times a day. In clinical trials, the efficacy and safety of the drug used during treatment lasting up to 6 weeks has been confirmed, therefore one course of treatment should be limited to 6 weeks.
(C)
